FDA CRL - Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA 214012) for inclisiran injection. The primary reason for the FDA's inability to approve the application in its current form relates to "objectionable conditions" identified at a manufacturing facility. These issues were noted during a review of records requested under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act. The FDA mandates satisfactory resolution of these conditions, which may involve a preapproval inspection or comprehensive responses from the facility, before the application can proceed to approval.

Beyond the facility-related concerns, the CRL also outlines other critical actions required for a successful resubmission. Novartis must provide a detailed safety update, adhering to the requirements of 21 CFR 314.50(d)(5)(vi)(b), which includes presenting new and combined safety data, re-tabulating adverse events, and providing updated exposure information. Comments on the proposed prescribing information are reserved until the application is otherwise adequate, and the previously acceptable proprietary name, Leqvio, must be resubmitted.

Novartis is required to fully address all deficiencies and resubmit the application within one year from the date of the letter, as per 21 CFR 314.110. Failure to do so may result in the application's withdrawal. The company has the option to request a meeting with the FDA to discuss the necessary steps for approval. Marketing of inclisiran injection is prohibited until formal written approval is granted.